Alzheimer's disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state

Journal of Alzheimer's Disease

Volumn 56, Issue 1, 2017, Pages 385-390

  Shen, Liang ^a   Liu, Lu ^a   Ji, Hong Fang ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

16S ribosomal RNA; Alzheimer's disease; APP PS1 mice; Gut microbiota

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-16); AMYLOID PRECURSOR PROTEIN; PEPTIDE FRAGMENT; PRESENILIN 1; RNA 16S;

AGE; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMAL; BEHAVIOR; C57BL MOUSE; COMPLICATION; DISEASE MODEL; ETIOLOGY; GENETICS; HUMAN; INTESTINE FLORA; MAZE TEST; METABOLISM; MOUSE; PHYSIOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIORAL SYMPTOMS; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; HUMANS; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRESENILIN-1; RNA, RIBOSOMAL, 16S;

EID: 85025593379     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160884     Document Type: Article

References (31)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191.
2. Prince M,Wimo A, Guerchet M, Ali G-C,Wu,Y-T, PrinaM (2015) Alzheimer's Disease InternationalWorld Alzheimer Report 2015, The global impact of dementia: An analysis of prevalence, incidence, costs and trends. Alzheimer's Disease International (ADI), London. Available from: https:// www.alz.co.uk/research/WorldAlzheimerReport2015.pdf
3. Barnes DE,YaffeK(2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10, 819-828.
4. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
5. Burns A, Iliffe S (2009) Alzheimer's disease. BMJ 338, b158.
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
7. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Emma J (2011) Alzheimer's disease. Lancet 377, 1019-1031.
8. Palmer AM (2002) Pharmacotherapy for Alzheimer's disease: Progress and prospects. Trends Pharmacol Sci 23, 426-433.
9. Nicholson JK (2012) Host-gut microbiota metabolic interactions. Science 336, 1262-1267.
10. Le CE, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, consortium MetaHIT, Bork P, Wang J, Ehrlich SD, Pedersen O, Guedon E, Delorme C, Layec S, Khaci G, van de Guchte M, Vandemeulebrouck G, Jamet A, Dervyn R, Sanchez N, Maguin E, Haimet F, Winogradski Y, Cultrone A, Leclerc M, Juste C, Blottiere H, Pelletier E, LePaslier D, Artiguenave F, Bruls T,Weissenbach J, Turner K, Parkhill J, Antolin M, Manichanh C, Casellas F, Boruel N, Varela E, Torrejon A, Guarner F, Denariaz G, Derrien M, van Hylckama Vlieg JE, Veiga P, Oozeer R, Knol J, Rescigno M, Brechot C, M'Rini C, Mérieux A, Yamada T (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541-546.
11. Abu-Shanab A, Quigley EM (2010) The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7, 691-701.
12. Shen J, Obin MS, Zhao L (2013) The gut microbiota, obesity and insulin resistance. Mol Aspects Med 34, 39-58.
13. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58, 120-127.
14. Knip M, Siljander H (2016) The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 12, 154-167.
15. Cani PD, DelzenneNM(2011) The gut microbiome as therapeutic target. Pharmacol Ther 130, 202-212.
16. Vassallo G, Mirijello A, Ferrulli A, Antonelli M, Landolfi R, Gasbarrini A, Addolorato G (2015) Review article: Alcohol and gut microbiota-the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. Aliment Pharmacol Ther 41, 917-927.
17. Alam MZ, Alam Q, Kamal MA, Abuzenadah AM, Haque A (2014) A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer's disease pathogenicity: An update. CNS Neurol Disord Drug Targets 13, 383-390.
18. Ghaisas S, Maher J, Kanthasamy A (2016) Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther 158, 52-62.
19. Shoemark DK, Allen SJ (2015) The microbiome and disease: Reviewing the links between the oral microbiome, aging, and Alzheimer's disease. J Alzheimers Dis 43, 725-738.
20. Bhattacharjee S, Lukiw WJ (2013) Alzheimer's disease and the microbiome. Front Cell Neurosci 7, 153.
21. Rhee SH, Pothoulakis C, Mayer EA (2009) Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 6, 306-314.
22. Romijn JA, Corssmit EP, Havekes LM, Pijl H (2008) Gutbrain axis. Curr Opin Clin Nutr Metab Care 11, 518-521.
23. Cryan JF, Dinan TG (2012) Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13, 701-712.
24. Littman DR, Pamer EG (2011) Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe 10, 311-323.
25. Serres S, Anthony DC, Jiang Y, Broom KA, Campbell SJ, Tyler DJ, van Kasteren SI,Davis BG, SibsonNR(2009) Systemic inflammatory response reactivates immune-mediated lesions in rat brain. J Neurosci 29, 4820-4828.
26. Erny D, Hrab?e de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E2, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, Schwierzeck V, Utermöhlen O, Chun E, Garrett WS, McCoy KD, Diefenbach A, Staeheli P, Stecher B, Amit I, Prinz M (2015) Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18, 965-977.
27. Harach T, Marungruang N, Dutilleul N, Cheatham V, Mc Coy KD, Neher JJ, Jucker M, Fak F, Lasser T, Bolmont T (2015) Reduction of Alzheimer's disease betaamyloid pathology in the absence of gut microbiota. arXiv:1509.02273.
28. Friedland RP (2015) Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimers Dis 45, 349-362.
29. Bauer PV, Hamr SC, Duca FA, Duca FA (2016) Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota. Cell Mol Life Sci 73, 737-755.
30. Singh V, Yeoh BS, Vijay-Kumar M (2016) Gut microbiome as a novel cardiovascular therapeutic target. Curr Opin Pharmacol 27, 8-12.
31. Shen L, Ji HF (2016) Intestinal microbiota and metabolic diseases: Pharmacological implications. Trends Pharmacol Sci 37, 169-171.